All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL
Bookmark this article
During the EHA2021 Virtual Congress, the ALL Hub spoke with André Baruchel, Hôpital Robert-Debré, Paris, FR, about the long-term follow-up from the ZUMA-4 trial.
Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL
In this video, Baruchel analyzes the results from the ZUMA-4 trial (NCT02625480) evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL). KTE-X19 is an autologous anti-CD19 chimeric antigen receptor T-cell therapy. He discusses patient characteristics, dosage, safety, efficacy, and toxicities, such as cytokine release syndrome and neurological adverse events.
Your opinion matters
15 votes - 18 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox